FDA Approves First Blood Test for Colorectal Cancer Screening

The new test, Shield, offers a less invasive option with 83% sensitivity, aiming to increase screening rates among eligible individuals.

Shield is the first blood test approved as a primary screening option for colorectal cancer.
The test meets Medicare coverage requirements and will be available commercially by fall.
Clinical trials showed Shield has an 83% sensitivity for detecting colorectal cancer.
The test is simpler and less time-consuming compared to colonoscopies and other methods.
Patients should follow up a positive blood test result with a colonoscopy for confirmation.